Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
26 03 2019
26 03 2019
Historique:
received:
24
07
2018
accepted:
21
11
2018
pubmed:
1
3
2019
medline:
18
12
2019
entrez:
1
3
2019
Statut:
ppublish
Résumé
To investigate the diagnostic value of serum neurofilament light chain (NFL) in patients with clear signs of parkinsonism but whose specific diagnosis was yet uncertain. Serum samples were collected from patients with clear signs of parkinsonism but with uncertain diagnosis at the inclusion. Clinical diagnoses of Parkinson disease (PD) and atypical parkinsonism disorders (APDs) were established after 3 years of follow-up and updated again after a maximum of 12 years in case longer follow-up data were available. Serum NFL was quantified by single molecule array in patients with PD (n = 55) and APD (n = 29, multiple system atrophy = 22, progressive supranuclear palsy = 7) and 53 nonneurologic controls. Serum NFL levels were elevated and differentiated the APD group (mean 23.8 ± 10.3 ng/L) from PD (mean 10.4 ± 4.9 ng/L) and controls (mean 11.5 ± 6.5 ng/L, Serum NFL levels are markedly elevated in APD compared to PD and discriminate APDs from PD with high accuracy. Serum NFL may be a useful clinical biomarker to identify APD, even at stages when clinical symptoms are not yet conclusive. This study provides Class II evidence that serum NFL levels accurately discriminate APDs from PD.
Identifiants
pubmed: 30814322
pii: WNL.0000000000007179
doi: 10.1212/WNL.0000000000007179
doi:
Substances chimiques
Neurofilament Proteins
0
neurofilament protein L
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1479-e1486Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 American Academy of Neurology.